Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L
about
Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individualsThe Significance of a Common Idiotype (1F7) on Antibodies against Human Immune Deficiency Virus Type 1 and Hepatitis C VirusConformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1Antibodies in HIV-1 vaccine development and therapyA global approach to HIV-1 vaccine developmentInduction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapyHuman Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus MacaquesHIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunizationStructure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodiesStructure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing EpitopeNeutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptorNew concepts in HIV-1 vaccine developmentPatterns of HIV/SIV Prevention and Control by Passive Antibody ImmunizationHigh-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responsesRecognition of membrane-bound fusion-peptide/MPER complexes by the HIV-1 neutralizing 2F5 antibody: implications for anti-2F5 immunogenicityComputational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity dataAn efficiently cleaved HIV-1 clade C Env selectively binds to neutralizing antibodiesCo-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cellsComposition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope GlycoproteinImmune-correlates analysis of an HIV-1 vaccine efficacy trialSurvivors Remorse: antibody-mediated protection against HIV-1.Current views on the potential for development of a HIV vaccine.HIV prevention transformed: the new prevention research agendaHuman immunodeficiency virus vaccine trialsClosing the door to human immunodeficiency virus.Recombinant expression, purification, and biophysical characterization of the transmembrane and membrane proximal domains of HIV-1 gp41.4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphismsInduction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy.Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV InfectionHIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells.Rational antibody-based HIV-1 vaccine design: current approaches and future directionsInternational multicenter study to assess a panel of reference materials for quantification of simian immunodeficiency virus RNA in plasmaMemory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses.A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.Characterization of neutralizing profiles in HIV-1 infected patients from whom the HJ16, HGN194 and HK20 mAbs were obtained.Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.Scaffolding to build a rational vaccine design strategy.Expression, purification and crystallization of CTB-MPR, a candidate mucosal vaccine component against HIV-1.
P2860
Q24635002-FD14E18B-0521-4AB6-B3EB-3876C000E278Q26767258-D11D4944-0751-4190-9A86-B36E6983AAB9Q26782237-F51F3D2C-0974-44FB-87FF-31719D123194Q27011574-D8B9E342-F769-40A7-B2DA-D8375CBFA68DQ27024614-A2CD63F2-9D93-4FCC-B908-CB9F02B03954Q27312171-CC236C7E-14B3-48B7-97EE-D6BFC9193839Q27313556-F89A15FC-86EB-4802-9A2E-539517F086D2Q27318508-838E3E02-6A1D-45E2-9B51-17D36F339338Q27324184-8FD983A6-C8D1-43F3-93AE-CE8C83749930Q27662155-4D03D056-84B2-444D-9FB1-FE7F30075075Q27674878-BAC88327-8E4A-407A-A086-4DC50ABA0310Q27675260-5C5EA212-3CEA-4468-8D38-62C7E4745232Q27684529-71D7E07B-3D41-4D83-B47B-ACA91CFC056DQ28067027-1F1EDD5F-29DA-48A9-8782-3F185FCA5DF5Q28068018-608A36D9-F29E-4124-8B8D-C4254664B151Q28242631-BA8B0B5D-C804-4828-9D17-B0693069AC5CQ28484544-64C323C4-4F05-46F6-B4C9-5D6697576EE8Q28535583-DD40A8E1-56F1-4866-B2BD-94BDB081F5EAQ28545185-F8D9ACA7-3619-4552-A0D1-FBB2CB21825DQ28732043-086C2540-B28A-44AE-8890-ACD5EDFEB457Q29306052-B6C307D7-7756-4135-8BFC-D95FAD75D53BQ29617377-DC7CCCD9-87B4-4002-9BC1-F1DDCBE0FDEFQ30238730-A97E78EF-AC1B-490C-A133-25D8902DCFE2Q30397595-2E111460-6149-49DA-AE9C-CFB34F578BDEQ30404963-A0992334-6CA3-4142-AEB4-C513765BB0E9Q30424366-DC86CE11-6247-4C00-9328-E0C960B5D7F7Q30428089-4BCA2AC2-F5D6-4AAC-8B50-3F82A3F2CB4BQ30601090-C4DA9EBC-0E00-4BB8-A40B-DF02045C8E20Q33547451-43EB2565-95B7-4E9C-9DA4-079D4C1EF643Q33611645-131585E7-455F-4012-A7C1-D244F9F95E3EQ33620546-0CB2E893-7847-4885-9892-F2FDCFBBBBB0Q33887674-98DBD0B3-F3F5-4E1A-8EE2-F700DDB87B30Q33937285-01E5E421-C8EF-4904-8FBC-7983714F21BBQ33963580-A569D05E-8F0F-476F-B128-B67C5B37AFE0Q34023249-19F53423-B276-4BC5-BDC5-02BAAA81B247Q34047445-C8D36F2F-61A6-4A09-A765-0BD6DD070617Q34053295-D99797ED-7A1B-425C-8BB5-9D979EFC247DQ34230556-7EF6F3D3-1330-45A2-8961-47C1866B7BCBQ34241394-5BC1FC09-B189-4669-AE4A-8054FEF34E19Q34242643-627D9788-565C-46E2-BD0A-A4318862932D
P2860
Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Broadly neutralizing monoclona ...... mmunodeficiency virus SHIVBa-L
@ast
Broadly neutralizing monoclona ...... mmunodeficiency virus SHIVBa-L
@en
type
label
Broadly neutralizing monoclona ...... mmunodeficiency virus SHIVBa-L
@ast
Broadly neutralizing monoclona ...... mmunodeficiency virus SHIVBa-L
@en
prefLabel
Broadly neutralizing monoclona ...... mmunodeficiency virus SHIVBa-L
@ast
Broadly neutralizing monoclona ...... mmunodeficiency virus SHIVBa-L
@en
P2093
P2860
P356
P1433
P1476
Broadly neutralizing monoclona ...... mmunodeficiency virus SHIVBa-L
@en
P2093
Ann J Hessell
David M Tehrani
Dennis R Burton
Donald N Forthal
Eva G Rakasz
Gary Landucci
Kimberly L Weisgrau
Michael Huber
Wayne C Koff
P2860
P304
P356
10.1128/JVI.01272-09
P407
P577
2009-11-11T00:00:00Z